Genetics

This blog post explores the exciting field of pharmacogenomics (PGx) and its potential to revolutionize how we treat multiple sclerosis (MS) by understanding how our genes affect our response to medications. It delves into research on established MS therapies like glatiramer acetate (GA) and interferon beta (IFNb), highlighting how genetic studies are uncovering markers that could predict who will respond best to each treatment and who might experience side effects. The post also discusses how PGx is already being used to assess the safety of drugs like natalizumab by identifying individuals at higher risk for certain complications. Ultimately, it paints a picture of a future where MS treatment is more personalized, moving away from the current trial-and-error approach towards giving each patient the optimal therapy right from the start, leading to better outcomes and safer care.